Professional Documents
Culture Documents
trade secrets or commercial property The prospective exclusive license Date: September 7, 2006.
such as patentable material, and territory may be worldwide and the Steven M. Ferguson,
personal information concerning field of use may be limited to the use Director, Division of Technology Development
individuals associated with the grant of a complete T-cell receptor MART–1 and Transfer, Office of Technology Transfer,
applications, the disclosure of which peptide restricted by HLA–A2 National Institutes of Health.
constitute a clearly unwarranted incorporated into a continuous T- [FR Doc. E6–15216 Filed 9–13–06; 8:45 am]
invasion of personal privacy. Lymphocyte cell line developed or BILLING CODE 4167–01–P
Therapeutic and Diagnostic Methods, to for public inspection and, to the extent programs that assess for co-occurring
CellCure A/S, which is located in permitted by law, will not be released disorders;
Aarhus, Denmark. The patent rights in under the Freedom of Information Act, • Increase percentage of treatment
these inventions have been assigned to programs that treat co-occurring
5 U.S.C. 552.
the United States of America. disorders through collaborative,
VerDate Aug<31>2005 20:23 Sep 13, 2006 Jkt 208001 PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 E:\FR\FM\14SEN1.SGM 14SEN1